Kristen P, Müller J G, Caffier H
Frauenklinik, Universität Würzburg, Germany.
Anticancer Res. 1997 Jul-Aug;17(4B):2869-71.
In a retrospective study, immunohistochemical determinations of p53 were performed on paraffinised tissue sections of 243 patients with node negative breast cancer. These patients were primary treated in the years 1980-1986 at the UFK-Würzburg. A complete follow up could be performed in 92% of all cases. The median follow up is at 102 month. The results have been correlated to other prognostic criteria and to the clinical course of the patients. In 77 of the 243 cases a positive immunohistochemical staining for p53 (31.7%) could be found. In 42 (17.3%) cancer specimens the p53 expression was over 5%. A significant correlation was found between p53 and tumour size (p = 0.05), ploidy (p < 0.001) and dynamic parameters of the cell cycle (S-phase-fraction, MIB1: p < 0.001). In univariate and multivariate analysis the expression of p53 did not effect disease-free or over-all survival of patients with node negative breast cancer.
在一项回顾性研究中，对243例淋巴结阴性乳腺癌患者的石蜡包埋组织切片进行了p53免疫组化检测。这些患者于1980年至1986年在维尔茨堡大学妇女医院接受初次治疗。所有病例中92%可进行完整随访。中位随访时间为102个月。研究结果已与其他预后标准及患者临床病程进行了关联分析。在243例病例中的77例（31.7%）发现p53免疫组化染色呈阳性。在42例（17.3%）癌组织标本中，p53表达超过5%。发现p53与肿瘤大小（p = 0.05）、倍体（p < 0.001）及细胞周期动力学参数（S期分数、MIB1：p < 0.001）之间存在显著相关性。在单因素和多因素分析中，p53表达对淋巴结阴性乳腺癌患者的无病生存期或总生存期均无影响。
